Investors' Rights Agreement providing registration rights and certain covenants; all rights except registration rights terminated upon the IPO closing on December 16, 2024.
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Jim DeTore
Chief Financial Officer and Interim Principal Financial and Accounting Officer
|
61 | Not stated | $96,000 | |
|
Arthur Kuan
Also a director
President
|
35 | Not stated | $11,928,401 | |
|
Vijay Kasturi
Chief Medical Officer
|
58 |
Since 2023
3 years
|
$3,599,947 | |
|
Joshua F. Patterson
General Counsel, Chief Compliance Officer and Secretary
|
50 |
Since 2024
2 years
|
$2,364,380 | |
|
Isabel Kalofonos
Chief Commercial Officer
Title from the Form 4 dated Oct 15, 2026
|
Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Investors' Rights Agreement providing registration rights and certain covenants; all rights except registration rights terminated upon the IPO closing on December 16, 2024.
Loading...